Amylyx Pharmaceuticals Quarterly Balance Sheet
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amylyx Pharmaceuticals financial position
As of Jun 30, 2026, Amylyx Pharmaceuticals reported total assets of $264.6 million, up 36.0% from a year earlier against total liabilities of $25.4 million. Shareholders' equity stood at $239.2 million, or 90.4% of assets. The company held $49.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 12.12, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Amylyx Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 49.33M | 229.14M | 226.65M | 225.18M | 58.09M | 59.76M | 77.39M | 71.84M | 75.00M | 170.55M | 170.20M | 135.26M |
| Short-Term Investments | 201.43M | 50.63M | 90.33M | 118.81M | 122.74M | 144.30M | 99.11M | 162.56M | 234.81M | 202.74M | 201.16M | 219.79M |
| Receivables | — | — | 88.00K | 132.00K | 103.00K | 300.00K | 447.00K | 1.73M | 4.09M | 20.35M | 40.05M | 29.35M |
| Inventory | — | — | — | — | — | — | — | — | — | — | 38.32M | 32.37M |
| Total Current Assets | 256.34M | 285.02M | 323.67M | 353.38M | 186.89M | 216.14M | 189.43M | 245.26M | 326.72M | 410.53M | 464.67M | 434.11M |
| Property, Plant & Equipment | 199.00K | 212.00K | 310.00K | 399.00K | 445.00K | 816.00K | 961.00K | 1.25M | 1.47M | 2.46M | 2.69M | 2.76M |
| Total Assets | 264.56M | 293.60M | 332.64M | 362.74M | 194.60M | 219.68M | 193.63M | 250.71M | 332.16M | 417.46M | 517.45M | 466.58M |
| Accounts Payable | 5.53M | 3.53M | 3.52M | 5.34M | 3.29M | 4.81M | 2.94M | 1.49M | 4.96M | 21.45M | 22.06M | 6.37M |
| Total Current Liabilities | 21.15M | 15.97M | 22.69M | 25.79M | 21.42M | 17.93M | 28.41M | 53.91M | 70.08M | 91.64M | 82.04M | 45.62M |
| Total Liabilities | 25.40M | 20.44M | 27.39M | 30.75M | 26.72M | 18.26M | 28.87M | 54.51M | 70.85M | 93.02M | 84.02M | 48.18M |
| Shareholders' Equity | 239.17M | 273.16M | 305.26M | 332.00M | 167.88M | 201.42M | 164.76M | 196.20M | 261.31M | 324.44M | 433.43M | 418.40M |
| Retained Earnings | -836.13M | -792.71M | -751.43M | -718.43M | -684.04M | -642.60M | -606.69M | -569.15M | -496.44M | -423.74M | -304.95M | -309.68M |
| Net Cash (Debt) | 250.76M | 279.77M | 316.98M | 343.99M | 180.83M | 204.07M | 176.50M | 234.40M | 309.81M | 373.29M | 371.36M | 355.05M |
| Shares Outstanding | 111.37M | 111.03M | 109.88M | 109.77M | 89.16M | 89.08M | 68.63M | 68.55M | 68.08M | 67.98M | 67.71M | 67.51M |
This table shows 12 quarterly periods of Amylyx Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow AMLX's reporting calendar. What is a balance sheet?